| Literature DB >> 34757595 |
Justin Carrard1, Chiara Guerini1, Julijana Ivanisevic2, Arno Schmidt-Trucksäss3, Christian Appenzeller-Herzog4, Denis Infanger1, Karsten Königstein1, Lukas Streese1, Timo Hinrichs1, Henner Hanssen1, Hector Gallart-Ayala5.
Abstract
BACKGROUND: Cardiorespiratory fitness (CRF) is a potent health marker, the improvement of which is associated with a reduced incidence of non-communicable diseases and all-cause mortality. Identifying metabolic signatures associated with CRF could reveal how CRF fosters human health and lead to the development of novel health-monitoring strategies.Entities:
Mesh:
Year: 2021 PMID: 34757595 PMCID: PMC8891196 DOI: 10.1007/s40279-021-01590-y
Source DB: PubMed Journal: Sports Med ISSN: 0112-1642 Impact factor: 11.136
Fig. 1Preferred Reporting Items for Systematic and Meta-Analysis (PRISMA) 2020 flow diagram. CPET cardiopulmonary exercise test, CRF cardiorespiratory fitness
Studies’ and participants’ characteristics
| References | Study design | Participants | Age | Female sex | VO2peak | Health conditions | Tissue samples | Metabolomics approach | Technology used |
|---|---|---|---|---|---|---|---|---|---|
| Stanford et al. [ | C | 39 | C1: 58.7 ± 2.5 C2: 29.4 ± 0.6 | C1: 0 C2: 50 | N/A | C1: overweight, obesity, arterial hypertension grade 1 C2: unknown smoking status | Serum | T (AQ) | LC–MS/MS |
| Duft et al. [ | RCT | 37 | CG: 14.72 ± 1.07 TG: 14.44 ± 1.04 | CG: 52 TG: 50 | CG: 35.18 ± 6.22 TG: 32.80 ± 6.15 | Overweight, obesity, unknown smoking status | Serum | T (AQ) | 1H NMR |
| Saleem et al. [ | L | 100 | 64 ± 6 | 15 | 21.7 ± 5.5 | Overweight, obesity, dyslipidemia, arterial hypertension, CAD, smoking, depression, musculoskeletal issues | Plasma | T (AQ) | HPLC–MS/MS |
| Kujala et al. [ | CS | 580 | 26.1 ± 6.5 | 0 | HF: 50.7 ± 4.2 LF: 31.8 ± 3.8 | Overweight, dyslipidemia, arterial hypertension, diabetes, smoking | Serum | T (AQ) | 1H NMR |
| Fabbri et al. [ | L | 443 | 68.9 ± 9.4 | 42 | 24.2 ± 6.8 | Dyslipidemia, arterial hypertension, prediabetes, diabetes, smoking | Plasma | T (AQ) | HPLC–MS/MS |
| Monnerat et al. [ | P | 14 | HF: 25.8 ± 50.3 LF: 26.0 ± 5.0 | 0 | HF: 76.3 ± 1.5 LF: 61.0 ± 3.5 | None | Plasma | U | UHPLC-HRMS |
| Lustgarten et al. [ | NRT | 77 | 24.4 ± 4.2 | 64 | 44.4 ± 10.8 | Overweight, obesity | Serum | U | UHPLC-MS/MS GC–MS |
| Harshman et al. [ | POC | 13 | C1: 26.67 ± 5.16 C2: 29.43 ± 3.36 | 0 | C1: 56.57 ± 10.40 C2: 43.03 ± 4.07 | None | Sweat | T (RQ) | LC–MS/MS |
| Nayor et al. [ | C | 471 | 53.0 ± 8.0 | 63 | 23.1 ± 7.1 | Overweight, dyslipidemia, arterial hypertension, diabetes, smoking | Plasma | T (AQ), U | LC–MS/MS |
| Contaifer et al. [ | CS | 49 | 57 | 25 | 14.0 ± 3.4 | Overweight, obesity, dyslipidemia, arterial hypertension, diabetes, heart failure | Plasma | U | LC–MS/MS GC–MS |
| Mueller-Hennessen et al. [ | CC | 41 | P: 51.5 ± 13.7 CG: 47.5 ± 12.8 | 0 | P: 21.0 ± 8.0 CG: 32.0 ± 6.0 | Overweight, dyslipidemia, arterial hypertension, diabetes, heart failure, smoking | Plasma | T (RQ) | LC–MS/MS GC–MS SPE-LC–MS/MS |
| Huffman et al. [ | RCT | 112 | 18–70 | 48 | 28.0 ± 5.8 | Overweight, obesity, dyslipidemia, arterial hypertension grade 1 | Skeletal muscle | T (AQ) | MS/MS GC–MS |
| Duft et al. [ | RCT | 22 | CG: 47.50 ± 6.20 TG: 48.60 ± 5.50 | 0 | CG: 29.10 ± 4.70 TG: 28.20 ± 4.70 | Obesity grade 1 | Serum | T (AQ) | 1H NMR |
| Morris et al. [ | RCT | 40 | 35.0 ± 14.0 | 50 | 41.1 ± 16.2 | Overweight, obesity | Plasma | T (AQ) | ESI–MS/MS |
| Contrepois et al. [ | C | 36 | 59.00 ± 8.00 | 42 | 30.60 ± 8.71 | Overweight, arterial hypertension, prediabetes, diabetes, smoking | Plasma | U, ST | LC–MS/MS Lipidyzer Platform |
| Kistner et al. [ | CS | 255 | 46.1 ± 16.9 | 42 | 38.8 ± 11.6 | None | Urine | T (AQ) | 1H NMR |
| Chorell et al. [ | I | 27 | HF TG: 28.16 ± 2.70 HF CG: 25.58 ± 1.77 LF TG: 26.30 ± 5.30 LF CG: 24.04 ± 1.83 | 0 | HF TG: 63.20 ± 2.93 HF CG: 63.67 ± 2.80 LF TG: 44.57 ± 5.62 LF CG: 42.71 ± 2.87 | None | Plasma | U | GC–MS/MS |
| Brennan et al. [ | RCT | 216 | CG: 52.3 ± 8.4 TG: 52.4 ± 7.8 | CG: 66 TG: 64 | CG: 29.2 ± 6.0 TG: 28.4 ± 5.1 | Overweight, obesity | Plasma | T (AQ) | LC–MS/MS |
| Morris et al. [ | CC | 65 | HF: 28.0 ± 9.0 LF: 36.0 ± 11.0 | 48 | HF: 54.9 ± 7.5 LF: 30.8 ± 7.2 | Overweight, obesity | Urine | U | GC–MS |
| Shi et al. [ | NRT | 20 | 29.42 ± 4.51 | 0 | 59.20 ± 5.90 | None | Serum | U | UHPLC-MS/MS |
| Bye et al. [ | NRT | 218 | HF: 49.50 LF: 49.50 | 58 | HF: 41.43 LF: 31.33 | None | Serum | U | 1H NMR |
| Michel et al. [ | CC | 40 | P: 23.1 ± 5.1 CG: 24.7 ± 6.6 | 35 | P: 28.8 ± 10.1 CG: 45.7 ± 6.4 | Fontan patients with systemic left ventricle | Serum | T (AQ) | LC–MS/MS |
AQ absolute quantification, C1 cohort/group 1, C2 cohort/group 2, C cohort, CAD coronary artery disease, CC case–control, CG control groups, CS cross-sectional, ESI–MS/MS electrospray ionization tandem mass spectrometry, GC–MS gas-chromatography tandem mass spectrometry, H NMR proton nuclear magnetic resonance, HF high fit, HPLC–MS/MS high-performance liquid-chromatography tandem mass spectrometry, I interventional, L longitudinal, LC–MS/MS liquid-chromatography tandem mass spectrometry, LW low fit, MS/MS tandem mass spectrometry, N/A not applicable, indicates that data were not reported in manuscripts and authors did not respond to our e-mail requests, NRT non-randomized trial, P in the column “age" and “VO peak” patients, P in the column study design pilot, POC proof of concept, RCT randomized controlled trial, RQ relative quantification, SD standard deviation, SPE-LC–MS/MS solid-phase extraction liquid-chromatography tandem mass spectrometry, ST semi-targeted, T targeted, TG training/test group, U untargeted, UHPLC-HRMS ultra-high performance liquid-chromatography tandem high-resolution mass spectrometry, VOpeak peak oxygen uptake
Risk of bias in individual studies evaluated with QUADOMICS
Green = yes, red = no, orange = unclear
Fig. 2Included metabolites on the super class level. a Metabolites super classes positively associated with cardiorespiratory fitness. b Metabolites super classes negatively associated with cardiorespiratory fitness. n number of metabolite species. Figure was created with the Mind the Graph platform (www.mindthegraph.com) and Adobe Illustrator 2021 (Adobe Inc., San Jose, CA, USA)
Fig. 3Included lipid and lipid-like molecules. a Lipids and lipid-like molecules positively associated with cardiorespiratory fitness, by class level. b Lipids and lipid-like molecules negatively associated with cardiorespiratory fitness, by class level. c Glycerophospholipids positively associated with cardiorespiratory fitness, by direct parent level. d Glycerophospholipids negatively associated with cardiorespiratory fitness, by direct parent level. LPC lyso-acylglycerophosphocholines, LPC-O lyso-alkylglycerophosphocholines, LPC-P lyso-alkenylglycerophosphocholines, LPE lyso-acylglycerophosphoethanolamines, n number of metabolite species, PC diacylglycerophosphocholines, PC-P alkenyl-acylglycerophosphocholines, PE diacylglycerophosphoethanolamines, PE-O alkyl-acylglycerophosphoethanolamines, PE-P alkenyl-acylglycerophosphoethanolamines, PI diacylglycerophosphoinositol. Figure was created with the Mind the Graph platform (www.mindthegraph.com) and Adobe Illustrator 2021 (Adobe Inc., San Jose, CA, USA)
Fig. 4Included organic acids and derivatives on the class level. a Organic acids and derivatives positively associated with cardiorespiratory fitness. b Organic acids and derivatives negatively associated with cardiorespiratory fitness. n number of metabolite species. Figure was created with the Mind the Graph platform (www.mindthegraph.com) and Adobe Illustrator 2021 (Adobe Inc., San Jose, CA, USA)
Metabolite species reported to be positively and negatively associated with CRF
| Metabolite super classes | Metabolite species | Studies reporting associations with CRF | |
|---|---|---|---|
| Positive | Negative | ||
| Lipids and lipid-like molecules | Nervonic acid | [ | [ |
| Vitamin A | [ | [ | |
| CE(20:4) | [ | [ | |
| CE(22:4) | [ | [ | |
| Organic acids and derivatives | Pyroglutamic acid | [ | [ |
| Histidine | [ | [ | |
| Methionine | [ | [ | |
| Cinnamoylglycine | [ | [ | |
| Phenylalanine | [ | [ | |
| Serine | [ | [ | |
| Tyrosine | [ | [ | |
| Organic oxygen compounds | 1,5-Anhydroglucitol | [ | [ |
| Kynurenine | [ | [ | |
| Organoheterocyclic compounds | C-Glycosyltryptophan | [ | [ |
CE cholesterol ester, CRF cardiorespiratory fitness
Metabolites species reported multiple times as positively associated with CRF
| Metabolite super classes | Metabolite species | Studies reporting positive associations with CRF |
|---|---|---|
| Benzenoids | Hippuric acid | [ |
| Lipids and lipid-like molecules | 12,13-diHOME | [ |
| Docosahexaenoic acid | [ | |
| PC(34:2) | [ | |
| LPC(18:0) | [ | |
| LPC(18:1) | [ | |
| LPC(18:2) | [ | |
| LPC(20:4) | [ | |
| SM(18:1;2/24:1) | [ | |
| CE(18:3) | [ | |
| CE(20:3) | [ | |
| Organic acids and derivatives | Asparagine | [ |
| Acetylglycine | [ | |
| Malic acid | [ | |
| Organoheterocyclic compounds | Bilirubin | [ |
CE cholesterol ester, CRF cardiorespiratory fitness, LPC lyso-acylglycerophosphocholines, PC diacylglycerophosphocholines, PC-P alkenyl-acylglycerophosphocholines, SM sphingomyelin
Metabolite species reported multiple times as negatively associated with CRF
| Metabolite super classes | Metabolite species | Studies reporting negative associations with CRF |
|---|---|---|
| Lipids and lipid-like molecules | CAR(3) propionylcarnitine | [ |
| CAR(6) hexanoylcarnitine | [ | |
| TAG(46:1), TAG(46:2), TAG(46:3), TAG(47:0), TAG(47:2), TAG(48:1), TAG(48:2), TAG(48:3), TAG(48:4), TAG(48:5), TAG(49:0), TAG(49:1), TAG(49:2), TAG(49:3), TAG(50:1), TAG(50:2), TAG(50:3), TAG(50:4), TAG(50:5), TAG(50:6), TAG(51:0), TAG(51:1), TAG(51:2), TAG(51:3), TAG(52:1), TAG(52:2), TAG(52:3), TAG(52:4), TAG(52:5), TAG(52:6), TAG(52:7), TAG(53:2), TAG(53:3), TAG(54:1), TAG(54:2), TAG(54:3), TAG(54:4), TAG(54:5), TAG(54:6), TAG(54:7), TAG(54:8), TAG(55:2), TAG(55:3), TAG(56:5) | [ | |
| γ-Tocopherol | [ | |
| Cer(18:1;2/16:0) | [ | |
| Cer(18:1;2/18:0) | [ | |
| Cer(18:1;2/20:0) | [ | |
| HexCer(18:1;2/18:0) | [ | |
| SM(18:1;2/18:0) | [ | |
| SM(18:1;2/18:1) | [ | |
| Glycocholic acid | [ | |
| Nucleosides, nucleotides, and analogs | Pseudouridine | [ |
| Organic acids and derivatives | Alanine | [ |
| Citrulline | [ | |
| Creatine | [ | |
| Lysine | [ | |
| Ornithine | [ | |
| Isoleucine | [ | |
| Leucine | [ | |
| Thyroxine | [ | |
| Proline | [ | |
| Lactic acid | [ | |
| Pyruvic acid | [ | |
| Organic nitrogen compounds | Carnitine | [ |
| Organic oxygen compounds | Gluconic acid | [ |
CAR carnitine, Cer ceramide, CRF cardiorespiratory fitness, HexCer hexosylceramide, SM sphingomyelin, TAG triacylglycerol
Fig. 5Metabolites associated with cardiorespiratory fitness (CRF) as potential driving forces of cardiometabolic health. Figure was created with the Mind the Graph platform (www.mindthegraph.com) and Adobe Illustrator 2021 (Adobe Inc., San Jose, CA, USA). BCAA branched-chain amino acids, LPCs lyso-acylglycerophosphocholines
| A panel of unique lipid species were found to be associated with cardiorespiratory fitness. |
| The majority of circulating glycerolipids, acylcarnitines, and ceramides were negatively associated with cardiorespiratory fitness, highlighting their link to poor cardiometabolic health. |
| Specific glycerophosphocholines and cholesterol esters were found to be positively associated with cardiorespiratory fitness, featuring their roles in health maintenance. |